secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001193125-25-179828
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences Q2 net loss $32.1M; cash $220.9M; JADE101 Phase 1 starts Q3
----------------------------------------------------------------------------

- Net loss of $32.1M for Q2 2025; R&D expense $22.5M, G&A $5.2M; non-cash stock comp $4.0M.
- Cash and cash equivalents of $220.9M as of June 30, 2025; expected runway through 2027.
- JADE101 preclinical data presented; Phase 1 healthy-volunteer study to begin Q3 2025 with interim data H1 2026.
- Appointed Brad Dahms as CFO; previously CFO at IDRx, Theseus, Selecta.
- JADE201 development candidate from JADE-002 program on track for clinic in H1 2026; details expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312525179828/0001193125-25-179828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312525179828/d82765d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-179828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer